Open an account

OmniAb

OABI · NASDAQ

$4.96+$0.27 (+5.76%)TodayMarket closed ·
Prev close $4.69

About OABI

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 89 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.

Employees
89
Headquarters
Emeryville, California
Listed
Oct 9, 2020
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
omniab.com

OABI key statistics

Market cap
721.14M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.25M
Volume
1.93M
Open price
$4.74
High today
$5.11
Low today
$4.74
52 Week high
$5.43
52 Week low
$1.30

OmniAb (OABI) at a glance

OmniAb (OABI) last traded at $4.96, with a market cap of 721.14M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.74 and $5.11. The current price is 4.6% above the day's low and 2.8% below its high.

Volume so far is 1.93M shares, above the average of 1.25M shares a day.

Over the past year OmniAb has ranged from $1.30 to $5.43, and now sits 89% of the way up that range.

OmniAb met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.1224.

The average analyst price target is $7.82, 57.7% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $7.82
Low
$4.04
Now
$4.96
High
$11.55

OABI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 26.7% on average.

  1. Q3 FY24: reported -$0.16 per share against an estimate of -$0.1401
  2. Q4 FY24: reported -$0.12 per share against an estimate of -$0.1149
  3. Q1 FY25: reported -$0.17 per share against an estimate of -$0.1673
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.1568
  5. Q3 FY25: reported -$0.14 per share against an estimate of -$0.1428
  6. Q4 FY25: reported -$0.11 per share against an estimate of -$0.0903
  7. Q1 FY26: reported -$0.06 per share against an estimate of -$0.102
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.1224

OABI news

  • Press releaseBusiness Wire

    OmniAb to Report Third Quarter 2026 Financial Results on October 30

  • Press releaseBusiness Wire

    OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

  • Press releaseBusiness Wire

    OmniAb to Host Investor & Analyst Day on October 6, 2026

  • Press releaseBusiness Wire

    OmniAb to Participate in Upcoming Investor Conferences

  • Avi Kapoor

    Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August

  • Akanksha Bakshi

    Why Is Omniab Stock Rallying After Eli Lilly Deal?

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Market-Moving News for August 17th

Similar companies

Companies in the same industry as OmniAb

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.